In the assessment of 12-month price targets, analysts unveil insights for Vanda Pharma, presenting an average target of $18.4 ...

Discovering Vanda Pharma: A Closer Look Vanda Pharmaceuticals Inc is a ... Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765 ...

Vanda Pharmaceuticals Inc ... formulation to treat schizophrenia; and Ponvory for the treatment of psoriasis and ulcerative colitis. Its pipeline products include HETLIOZ (tasimelteon) to ...

Vanda Pharmaceuticals Inc. (NASDAQ ... management's cautious optimism about the company's near-term prospects. VNDA's current product lineup is anchored by Fanapt, PONVORY, and HETLIOZ. Fanapt, in ...

Vanda Pharmaceuticals Inc. is looking to add imsidolimab to its product portfolio for rare orphan disorders ... as well as its anti-inflammatory portfolio that includes Ponvory® for multiple sclerosis ...

Vanda Pharmaceuticals also aims for significant long-term growth, targeting $750 million in annual revenue from its psychiatry products by 2030. This article was generated with the support of AI ...

Vanda Pharmaceuticals (NASDAQ:VNDA – Free Report) had its price target upped by HC Wainwright from $18.00 to $20.00 in a research note issued to investors on Tuesday morning,Benzinga reports.

H.C. Wainwright raised the firm’s price target on Vanda Pharmaceuticals (VNDA) to $20 from $18 and keeps a Buy rating on the shares. The firm added imsidolimab to its valuation assessment.

Vanda Pharmaceuticals also aims for significant long-term growth, targeting $750 million in annual revenue from its psychiatry products by 2030. This article was generated with the support of AI and ...